The high-glucose (40 mM)–mediated decrease in myogenic tone or dilation was unaffected by
l-NAME and 4-aminoguanidine, which block cNOS and iNOS, respectively. Dilation was also unaffected by 30 mM KCl, which partially depolarizes smooth muscle membrane and prevents the action of EDHF. A combination of
l-NAME and KCl also had no effect. These observations rule out the involvement of NO and EDHF in the dilatory response produced by high glucose. Indomethacin, a cyclooxygenase inhibitor that blocks the release of the dilating factor PGI
2, was not tried in these experiments, because we had observed earlier that indomethacin produces dilation and decreases myogenic tone in this artery, suggesting a role for cyclooxygenase products in the development of myogenic tone.
3 Miconazole, a nonselective inhibitor of Cyt-P450 enzymes and dihydro-ouabain, an inhibitor of Na
+,K
+-ATPase, completely prevented a high-glucose–mediated decrease in myogenic tone. Because this dilation was not observed in the absence of endothelium, these observations imply that high glucose induces the release of an endothelial factor or radical that produces smooth muscle relaxation by activating Na
+,K
+-ATPase on smooth muscle membrane. This description well fits to the actions of EET. Future investigations involving biochemical and analytical methods are mandatory to support the findings from the present functional study. There is no indication in the literature of the involvement of an EET-Na
+,K
+-ATPase pathway in the dilatory effects of high glucose. Instead, contrasting observations were made by Xia et al.
34 in rat mesenteric smooth muscle cells and Gupta et al.
15 in rabbit aorta proposing the inhibition of Na
+,K
+-ATPase as underlying mechanism of high-glucose–mediated constriction. These observations show either vascular-bed–dependent variations or variations with the experimental system being used.